Therapy Areas: Oncology
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada
7 March 2025 - US-based drug discovery and development company Bantam Pharmaceutical announced on Thursday that it is proceeding with a Phase 1 clinical trial evaluating BTM-3566 in relapsed/refractor...
ImmunoGenesis reports first patient dosed in Phase 1/2 clinical trial of IMGS-101 (evofosfamide) combination
7 March 2025 - Clinical-stage biotech company ImmunoGenesis announced on Thursday that the first patient has been dosed in its Phase 1/2 clinical trial of its hypoxia reversal agent IMGS-101 (evofosfa...
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
6 March 2025 - Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...
Sectra announces US health system expansion with digital pathology
6 March 2025 - Medical technology company Sectra (STO:SECT-B) announced on Thursday that a US health system will expand its enterprise imaging solution with digital pathology.This addition aims to enh...
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
5 March 2025 - Biopharmaceutical companies Jazz Pharmaceuticals plc (Nasdaq:JAZZ) and Chimerix (Nasdaq:CMRX) on Wednesday announced a definitive agreement for Jazz to acquire Chimerix for USD8.55 per ...
Genentech announces FDA acceptance of supplemental Biologics License Application for Gazyva to treat lupus nephritis treatment
5 March 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted its supp...